SHR1701

Phase 2Small molecule

FFudan University

SHR1701 is one of 4 small molecule programs targeting Advanced Gastric Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Gastric CancerRecruiting

Advanced Gastric CancerPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Advanced Gastric Cancer

#DrugCompanyPhaseTrials

Rilvegostomig

AstraZeneca

Phase 2

1 2

SHR2554

JJiangsu HengRui Medicine Co., Ltd.

Phase 2

1 3

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Phase 2

1 4

SHR1701

FFudan University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Advanced Gastric Cancer

NCT07294664

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment

Unknown status·SShandong Cancer Hospital and Institute·Phase 2·NCT04560244·15 enrolled

Lymphoma1 trial

Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas

Unknown status·—·Phase 1/2·NCT04407741·100 enrolled

Breast Cancer1 trial

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer

Unknown status·FFudan University·Phase 2·NCT04355858·319 enrolled

Advanced Gastric Cancer1 trial

Clinical Study of SHR1701 in Combination With CAPOX and SHR2554 or Apatinib for First-line Treatment of Advanced Gastric Cancer

Recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT07294664·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for SHR1701. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SHR1701 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SHR1701. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFudan University

SHR1701

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Lymphoma1 trial

Breast Cancer1 trial

Advanced Gastric Cancer1 trial

References

Drug Info

Quick Facts

Related News